-
公开(公告)号:US20210032263A1
公开(公告)日:2021-02-04
申请号:US16964274
申请日:2019-01-25
申请人: Exelixis, Inc.
发明人: Lynne Canne Bannen , Minna Bui , Faming Jiang , Yong Wang , Wei Xu
IPC分类号: C07D491/147 , C07D401/12 , C07D413/14 , C07D401/14 , C07D471/04
摘要: Disclosed herein are compounds of Formula I′. Compounds of Formula I′ inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
-
公开(公告)号:US20210030737A1
公开(公告)日:2021-02-04
申请号:US16095221
申请日:2017-04-18
申请人: EXELIXIS, INC.
发明人: Sara M. TOLANEY , Dan G. DUDA
IPC分类号: A61K31/47 , A61K47/38 , A61K47/26 , A61K47/02 , A61K47/12 , A61K9/28 , A61K38/17 , A61K39/395 , A61P35/00
摘要: Disclosed is a method of treating triple negative breast cancer in a human patient, comprising administering to the patient an amount of cabozantinib or a pharmaceutically acceptable salt thereof, wherein the amount of cabozantinib is sufficient to activate the immune system.
-
公开(公告)号:US10166225B2
公开(公告)日:2019-01-01
申请号:US14346570
申请日:2012-09-20
申请人: Exelixis, Inc.
发明人: Dana T. Aftab , Douglas Clary
摘要: This invention is directed to the treatment of osteoporosis using N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
-
公开(公告)号:US09861624B2
公开(公告)日:2018-01-09
申请号:US14398188
申请日:2013-05-02
申请人: Exelixis, Inc.
发明人: Dana T. Aftab
IPC分类号: A61K31/47
CPC分类号: A61K31/47
摘要: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteolytic bone metastases, with a dual inhibitor of MET and VEGF.
-
公开(公告)号:US20170224670A1
公开(公告)日:2017-08-10
申请号:US15519012
申请日:2015-10-14
申请人: Exelixis, Inc.
发明人: Keiran Smalley
IPC分类号: A61K31/46 , A61K31/437
CPC分类号: A61K31/46 , A61K31/437 , A61K2300/00
摘要: This invention relates to the combination of vemurafenib and the heat shock protein 90 (HSP90) inhibitor XL888 to treat melanoma, particularly BRAF V600 mutant melanoma in patients in need of such treatment.
-
公开(公告)号:US09670212B2
公开(公告)日:2017-06-06
申请号:US13822809
申请日:2011-09-14
申请人: James William Leahy
发明人: James William Leahy
IPC分类号: C07D473/38 , C07D215/12 , C07D215/14 , C07D215/38 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D413/14 , C07D473/34 , C07D487/04 , C07D495/04 , C07D519/00 , C07D213/30 , C07D213/38 , C07D295/125
CPC分类号: C07D519/00 , C07D213/30 , C07D213/38 , C07D215/12 , C07D215/14 , C07D215/38 , C07D241/44 , C07D295/125 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D413/14 , C07D417/14 , C07D473/34 , C07D473/38 , C07D487/04 , C07D495/04
摘要: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
-
87.
公开(公告)号:US09346807B2
公开(公告)日:2016-05-24
申请号:US13822840
申请日:2011-09-14
申请人: Patrick Kearney
发明人: Patrick Kearney
IPC分类号: C07D473/34 , C07D471/10 , C07D473/04
CPC分类号: C07D473/34 , C07D471/10 , C07D473/04
摘要: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
摘要翻译: 本发明涉及式I化合物及其药学上可接受的盐或溶剂合物,以及制备和使用该化合物的方法。
-
公开(公告)号:US20140378436A9
公开(公告)日:2014-12-25
申请号:US13989366
申请日:2011-11-23
申请人: Kenneth D. Rice
发明人: Kenneth D. Rice
IPC分类号: C07D413/14 , C07D471/10 , C07D471/04
CPC分类号: C07D413/14 , C07D413/04 , C07D413/06 , C07D417/14 , C07D451/02 , C07D451/06 , C07D451/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D513/04 , C07D519/00
摘要: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
-
公开(公告)号:US08791102B2
公开(公告)日:2014-07-29
申请号:US13124604
申请日:2009-10-16
申请人: Mohamed Abdulkader Ibrahim , Joon Won Jeong , Henry William Beecroft Johnson , Patrick Kearney , James W. Leahy , Gary L. Lewis , Robin Tammie Noguchi , John M. Nuss
发明人: Mohamed Abdulkader Ibrahim , Joon Won Jeong , Henry William Beecroft Johnson , Patrick Kearney , James W. Leahy , Gary L. Lewis , Robin Tammie Noguchi , John M. Nuss
IPC分类号: A61K31/4196 , A61K31/417 , A61K31/4192 , A61K31/167 , A61K31/341 , A61K31/4015 , A61K31/455 , A61K31/506 , A61K31/541 , A61K31/55 , A61P35/00 , A61P35/02 , C07D207/452 , C07D213/56 , C07D223/04 , C07D307/54 , C07D403/04 , C07D403/06 , C07D417/06
CPC分类号: C07D207/06 , C07D207/10 , C07D207/16 , C07D207/277 , C07D207/452 , C07D209/08 , C07D211/14 , C07D211/58 , C07D213/56 , C07D215/06 , C07D233/61 , C07D233/64 , C07D235/14 , C07D237/20 , C07D239/42 , C07D241/12 , C07D241/44 , C07D249/04 , C07D249/08 , C07D257/04 , C07D261/08 , C07D263/32 , C07D265/30 , C07D277/36 , C07D279/12 , C07D307/14 , C07D307/16 , C07D307/56 , C07D307/85 , C07D317/60 , C07D333/24 , C07D401/06 , C07D403/06 , C07D403/12 , C07D403/14 , C07D407/06 , C07D407/10 , C07D409/06 , C07D409/14 , C07D413/06 , C07D417/06 , C07D417/12
摘要: This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particular, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor antagonist, such as in the treatment of cancer, and processes for making the S1P1 receptor antagonists.
摘要翻译: 本公开涉及鞘氨醇-1-磷酸(S1P)受体拮抗剂,包含S1P受体拮抗剂的组合物,以及用于制备S1P受体拮抗剂的方法和方法。 特别地,本公开内容涉及鞘氨醇-1-磷酸酯1(S1P1)受体拮抗剂,包含S1P1受体拮抗剂的组合物和使用S1P1受体拮抗剂的方法,例如用于治疗癌症,以及制备S1P1受体拮抗剂的方法 。
-
公开(公告)号:US20140179736A1
公开(公告)日:2014-06-26
申请号:US14115236
申请日:2012-05-02
申请人: Gisela Schwab , Dana T. Aftab
发明人: Gisela Schwab , Dana T. Aftab
IPC分类号: C07D215/233
CPC分类号: C07D215/233 , A61K31/536
摘要: This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.
摘要翻译: 本发明涉及癌症,特别是肺癌,乳腺癌,黑素瘤,肾细胞癌,转移至骨的甲状腺癌的治疗。 本发明还涉及一种用于治疗需要这种治疗的个体中的骨癌疼痛的方法,包括向个体施用有效量的式I化合物。
-
-
-
-
-
-
-
-
-